Madrigal Pharmaceuticals, Inc. (MDGL) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 11.06B USD. 52-week range 393.61 to 615.00 USD. Data as of 2026-10-09.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.